Clinical Trials Logo

Clinical Trial Summary

This study will collect MRI from healthy volunteer boys and boys with Duchenne Muscular Dystrophy (DMD) to help researchers identify and validate cardiac MRI biomarkers to better understand the health of the heart and changes in heart health over time in boys with DMD. Currently, there is a lack of sufficiently well characterized cardiac MRI biomarkers that can serve as endpoints for detecting on-target and/or off-target cardiac effects during clinical drug trials for boys with DMD. Consequently, the first objective is to identify and characterize several cardiac MRI biomarkers for boys with DMD.


Clinical Trial Description

The second objective is to use their well-characterized cardiac MRI biomarkers and define their sensitivity for detecting early cardiac involvement. The final objective is to use these validated cardiac MRI biomarkers to better understand the genotype-phenotype correlation in boys with DMD, which to date remain tenuous. The investigators propose a pilot study to explore cardiac genotype-phenotype correlations in boys with DMD and outlier phenotypes using approaches they have pioneered for skeletal muscle. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02834650
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase N/A
Start date February 1, 2017
Completion date March 30, 2022

See also
  Status Clinical Trial Phase
Terminated NCT01865084 - A Study of Tadalafil for Duchenne Muscular Dystrophy Phase 3
Completed NCT00243789 - Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy Phase 1/Phase 2
Completed NCT00033189 - An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy Phase 2
Completed NCT03703882 - Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy Phase 3
Enrolling by invitation NCT04626674 - A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Completed NCT02286947 - Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy Phase 2
Completed NCT03406780 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2
Completed NCT01826487 - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Phase 3
Completed NCT02710591 - Rimeporide in Patients With Duchenne Muscular Dystrophy Phase 1
Completed NCT01826422 - Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients N/A
Completed NCT00102453 - Pentoxifylline in Duchenne Muscular Dystrophy Phase 1/Phase 2
Terminated NCT02090959 - An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy Phase 3
Recruiting NCT05833633 - Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations
Completed NCT05209087 - Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy
Completed NCT03789734 - Safety Study of BLS-M22 in Healthy Volunteers Phase 1
Recruiting NCT05126758 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 3
Completed NCT00016653 - Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Phase 2/Phase 3
Completed NCT03127241 - User-centred Assistive System for Arm Functions in Neuromuscular Subjects N/A
Completed NCT03490214 - Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography N/A
Completed NCT03179631 - Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Phase 3